• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

使用前列腺健康指数预测灰色地带前列腺癌的列线图：前瞻性多中心研究

Nomogram Using Prostate Health Index for Predicting Prostate Cancer in the Gray Zone: Prospective, Multicenter Study.

作者信息

Chung Jae Hoon, Kim Jeong Hyun, Lee Sang Wook, Park Hongzoo, Song Geehyun, Song Wan, Kang Minyong, Sung Hyun Hwan, Jeon Hwang Gyun, Jeong Byong Chang, Seo Seong Il, Lee Hyun Moo, Jeon Seong Soo

机构信息

Department of Urology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.

Department of Urology, Kangwon National University School of Medicine, Chuncheon, Korea.

出版信息

World J Mens Health. 2024 Jan;42(1):168-177. doi: 10.5534/wjmh.220223. Epub 2023 Apr 10.

DOI:10.5534/wjmh.220223
PMID:37118959
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10782127/
Abstract

PURPOSE

To create a nomogram that can predict the probability of prostate cancer using prostate health index (PHI) and clinical parameters of patients. And the optimal cut-off value of PHI for prostate cancer was also assessed.

MATERIALS AND METHODS

A prospective, multi-center study was conducted. PHI was evaluated prior to biopsy in patients requiring prostate biopsy due to high prostate-specific antigen (PSA). Among screened 1,010 patients, 626 patients with clinically suspected prostate cancer with aged 40 to 85 years, and with PSA levels ranging from 2.5 to 10 ng/mL were analyzed.

RESULTS

Among 626 patients, 38.82% (243/626) and 22.52% (141/626) were diagnosed with prostate cancer and clinically significant prostate cancer, respectively. In the PSA 2.5 to 4 ng/mL group, the areas under the curve (AUCs) of the nomograms for overall prostate cancer and clinically significant prostate cancer were 0.796 (0.727-0.866; p<0.001), and 0.697 (0.598-0.795; p=0.001), respectively. In the PSA 4 to 10 ng/mL group, the AUCs of nomograms for overall prostate cancer and clinically significant prostate cancer were 0.812 (0.783-0.842; p<0.001), and 0.839 (0.810-0.869; p<0.001), respectively.

CONCLUSIONS

Even though external validations are necessary, a nomogram using PHI might improve the prediction of prostate cancer, reducing the need for prostate biopsies.

摘要

目的

创建一种列线图，该列线图可利用前列腺健康指数（PHI）和患者的临床参数预测前列腺癌的发生概率。同时，还评估了用于前列腺癌诊断的PHI最佳临界值。

材料与方法

开展了一项前瞻性多中心研究。对因前列腺特异性抗原（PSA）水平升高而需要进行前列腺活检的患者，在活检前评估其PHI。在筛选出的1010例患者中，分析了626例年龄在40至85岁之间、PSA水平在2.5至10 ng/mL之间、临床怀疑患有前列腺癌的患者。

结果

在626例患者中，分别有38.82%（243/626）和22.52%（141/626）被诊断为前列腺癌和临床意义显著的前列腺癌。在PSA为2.5至4 ng/mL组中，总体前列腺癌和临床意义显著的前列腺癌列线图的曲线下面积（AUC）分别为0.796（0.727 - 0.866；p<0.001）和0.697（0.598 - 0.795；p = 0.001）。在PSA为4至10 ng/mL组中，总体前列腺癌和临床意义显著的前列腺癌列线图的AUC分别为0.812（0.783 - 0.842；p<0.001）和0.839（0.810 - 0.869；p<0.001）。

结论

尽管需要进行外部验证，但使用PHI的列线图可能会改善前列腺癌的预测，减少前列腺活检的需求。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/33f7/10782127/1e5d8f0f6d05/wjmh-42-168-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/33f7/10782127/8202b6daced5/wjmh-42-168-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/33f7/10782127/3f70b4803cbb/wjmh-42-168-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/33f7/10782127/1e5d8f0f6d05/wjmh-42-168-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/33f7/10782127/8202b6daced5/wjmh-42-168-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/33f7/10782127/3f70b4803cbb/wjmh-42-168-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/33f7/10782127/1e5d8f0f6d05/wjmh-42-168-g003.jpg

相似文献

1
Nomogram Using Prostate Health Index for Predicting Prostate Cancer in the Gray Zone: Prospective, Multicenter Study.使用前列腺健康指数预测灰色地带前列腺癌的列线图：前瞻性多中心研究
World J Mens Health. 2024 Jan;42(1):168-177. doi: 10.5534/wjmh.220223. Epub 2023 Apr 10.
2
Multicenter European external validation of a prostate health index-based nomogram for predicting prostate cancer at extended biopsy.基于前列腺健康指数的列线图对扩展活检前列腺癌预测的多中心欧洲外部验证。
Eur Urol. 2014 Nov;66(5):906-12. doi: 10.1016/j.eururo.2013.12.005. Epub 2013 Dec 16.
3
[Prospective validation of a nomogram predictive of a positive initial prostate biopsy].[预测前列腺初次活检阳性的列线图的前瞻性验证]
Actas Urol Esp. 2010 Jan;34(1):35-42.
4
Comparisons of the diagnostic accuracy across prostate health index, prostate health index density, and percentage free prostate-specific antigen for clinically significant prostate cancer: a prospective diagnostic study.前列腺健康指数、前列腺健康指数密度和游离前列腺特异性抗原百分比对临床显著性前列腺癌的诊断准确性比较：一项前瞻性诊断研究。
Transl Androl Urol. 2023 Mar 31;12(3):425-432. doi: 10.21037/tau-23-80. Epub 2023 Mar 28.
5
A nomogram for prediction of prostate cancer on multi-core biopsy using age, serum prostate-specific antigen, prostate volume and digital rectal examination in Singapore.新加坡利用年龄、血清前列腺特异性抗原、前列腺体积和直肠指检对多芯活检前列腺癌进行预测的列线图。
Asia Pac J Clin Oncol. 2017 Oct;13(5):e348-e355. doi: 10.1111/ajco.12596. Epub 2016 Sep 19.
6
Prostate health index significantly reduced unnecessary prostate biopsies in patients with PSA 2-10 ng/mL and PSA >10 ng/mL: Results from a Multicenter Study in China.前列腺健康指数显著减少了PSA为2 - 10 ng/mL和PSA>10 ng/mL患者的不必要前列腺活检：一项中国多中心研究的结果
Prostate. 2017 Aug;77(11):1221-1229. doi: 10.1002/pros.23382. Epub 2017 Jun 30.
7
The roles of prostate-specific antigen (PSA) density, prostate volume, and their zone-adjusted derivatives in predicting prostate cancer in patients with PSA less than 20.0 ng/mL.前列腺特异性抗原（PSA）密度、前列腺体积及其区域校正衍生物在预测 PSA 低于 20.0 ng/mL 的患者前列腺癌中的作用。
Andrology. 2017 May;5(3):548-555. doi: 10.1111/andr.12322.
8
Developing a nomogram based on multiparametric magnetic resonance imaging for forecasting high-grade prostate cancer to reduce unnecessary biopsies within the prostate-specific antigen gray zone.基于多参数磁共振成像开发一种列线图，用于预测高级别前列腺癌，以减少前列腺特异性抗原灰色区域内不必要的活检。
BMC Med Imaging. 2017 Feb 1;17(1):11. doi: 10.1186/s12880-017-0184-x.
9
Development of a nomogram combining multiparametric magnetic resonance imaging and PSA-related parameters to enhance the detection of clinically significant cancer across different region.开发一种结合多参数磁共振成像和前列腺特异性抗原（PSA）相关参数的列线图，以提高不同区域临床显著性癌症的检测率。
Prostate. 2022 Apr;82(5):556-565. doi: 10.1002/pros.24302. Epub 2022 Jan 31.
10
MRI-Based Radiomics Nomogram for Predicting Prostate Cancer with Gray-Zone Prostate-Specific Antigen Levels to Reduce Unnecessary Biopsies.基于MRI的影像组学列线图用于预测处于前列腺特异性抗原灰色区域水平的前列腺癌，以减少不必要的活检。
Diagnostics (Basel). 2022 Dec 1;12(12):3005. doi: 10.3390/diagnostics12123005.

引用本文的文献

1
The research progress on diagnostic indicators related to prostate-specific antigen gray-zone prostate cancer.与前列腺特异性抗原灰色区域前列腺癌相关的诊断指标研究进展
BMC Cancer. 2025 Aug 4;25(1):1264. doi: 10.1186/s12885-025-14505-1.
2
Development and validation of biopsy free nomograms for predicting clinically significant prostate cancer in men with PI-RADS 4 and 5 lesions.用于预测PI-RADS 4和5类病变男性患者临床显著性前列腺癌的非活检列线图的开发与验证
Sci Rep. 2025 Jan 20;15(1):2506. doi: 10.1038/s41598-025-86607-6.

本文引用的文献

1
Prostate Health Index Density Outperforms Prostate Health Index in Clinically Significant Prostate Cancer Detection.前列腺健康指数密度在临床意义重大的前列腺癌检测方面优于前列腺健康指数。
Front Oncol. 2021 Nov 19;11:772182. doi: 10.3389/fonc.2021.772182. eCollection 2021.
2
Strategy for Prostate Cancer Patients with Low Prostate Specific Antigen Level (2.5 to 4.0 ng/mL).前列腺特异性抗原水平（2.5 至 4.0ng/ml）较低的前列腺癌患者的治疗策略。
J Korean Med Sci. 2020 Oct 26;35(41):e342. doi: 10.3346/jkms.2020.35.e342.
3
Negative Predictive Value of Multiparametric Magnetic Resonance Imaging in the Detection of Clinically Significant Prostate Cancer in the Prostate Imaging Reporting and Data System Era: A Systematic Review and Meta-analysis.
前列腺影像报告和数据系统时代多参数磁共振成像在检测临床显著性前列腺癌中的阴性预测值：一项系统评价和荟萃分析
Eur Urol. 2020 Sep;78(3):402-414. doi: 10.1016/j.eururo.2020.03.048. Epub 2020 May 20.
4
A Multicentre Evaluation of the Role of the Prostate Health Index (PHI) in Regions with Differing Prevalence of Prostate Cancer: Adjustment of PHI Reference Ranges is Needed for European and Asian Settings.一项前列腺健康指数（PHI）在前列腺癌发病地区不同的作用的多中心评估：需要对欧洲和亚洲人群的 PHI 参考范围进行调整。
Eur Urol. 2019 Apr;75(4):558-561. doi: 10.1016/j.eururo.2018.10.047. Epub 2018 Nov 2.
5
Performance of the Prostate Health Index in predicting prostate biopsy outcomes among men with a negative digital rectal examination and transrectal ultrasonography.前列腺健康指数在预测直肠指检和经直肠超声检查结果均为阴性的男性前列腺活检结果中的表现。
Asian J Androl. 2016 Jul-Aug;18(4):633-8. doi: 10.4103/1008-682X.172823.
6
Development and external validation of a prostate health index-based nomogram for predicting prostate cancer.用于预测前列腺癌的基于前列腺健康指数的列线图的开发与外部验证
Sci Rep. 2015 Oct 16;5:15341. doi: 10.1038/srep15341.
7
Clinical performance of serum prostate-specific antigen isoform [-2]proPSA (p2PSA) and its derivatives, %p2PSA and the prostate health index (PHI), in men with a family history of prostate cancer: results from a multicentre European study, the PROMEtheuS project.家族性前列腺癌病史男性患者中血清前列腺特异性抗原同工型 [-2]proPSA（p2PSA）及其衍生物%p2PSA 和前列腺健康指数（PHI）的临床性能：来自多国欧洲研究——PROMEtheuS 项目的结果。
BJU Int. 2013 Aug;112(3):313-21. doi: 10.1111/bju.12217.
8
Timing of curative treatment for prostate cancer: a systematic review.前列腺癌的根治性治疗时机：系统评价。
Eur Urol. 2013 Aug;64(2):204-15. doi: 10.1016/j.eururo.2013.02.024. Epub 2013 Feb 22.
9
Multicenter evaluation of [-2]proprostate-specific antigen and the prostate health index for detecting prostate cancer.多中心评估 [-2] 前列腺特异性抗原和前列腺健康指数在前列腺癌检测中的应用。
Clin Chem. 2013 Jan;59(1):306-14. doi: 10.1373/clinchem.2012.195784. Epub 2012 Dec 4.
10
From prostate-specific antigen (PSA) to precursor PSA (proPSA) isoforms: a review of the emerging role of proPSAs in the detection and management of early prostate cancer.从前列腺特异性抗原（PSA）到前体 PSA（proPSA）同工型：对 proPSA 在早期前列腺癌检测和管理中新兴作用的综述。
BJU Int. 2013 Oct;112(6):717-28. doi: 10.1111/j.1464-410X.2012.11329.x. Epub 2012 Jul 3.